New Evidence Challenges Cyproterone Acetate Use in Gender-Affirming Hormone Therapy
Overview
A randomized clinical trial found no significant difference in breast development or patient satisfaction between cyproterone acetate and spironolactone as adjuncts to feminizing hormone therapy. Cyproterone acetate showed greater testosterone suppression but carries potential risks not seen with spironolactone.
Background
Cyproterone acetate and spironolactone are commonly used antiandrogen agents in feminizing gender-affirming hormone therapy. Cyproterone acetate, a synthetic progesterone derivative, is widely used in Europe and Australia but not FDA-approved in the US. Spironolactone, a mineralocorticoid antagonist, is the predominant agent in the US and generally well tolerated. Concerns about cyproterone acetate include dyslipidemia, hyperprolactinemia, and rare meningioma formation.
Data Highlights
Outcome
Mean Difference
P Value
Breast chest distance
0.27 cm
0.6
Estimated breast volume
17.26 mL
0.3
Patient-reported breast satisfaction
Not significant
0.5
Key Findings
No statistically significant difference in breast development or breast satisfaction between cyproterone acetate and spironolactone groups after 6 months.
Cyproterone acetate achieved greater serum testosterone suppression than spironolactone.
No evidence supporting the existence of spironolactone-associated "brain fog" based on Patient Health Questionnaire 9 results.
Cyproterone acetate is linked to potential adverse effects including dyslipidemia, mild hyperprolactinemia, and rare meningioma formation.
Spironolactone is generally well tolerated with rare but serious risk of hyperkalemia.
Shared decision-making is recommended given the lack of breast development benefit and known risks of cyproterone acetate.
Clinical Implications
Clinicians should consider spironolactone as the preferred adjunct antiandrogen in feminizing hormone therapy due to its safety profile and comparable efficacy in breast development. The greater testosterone suppression by cyproterone acetate may not translate into clinical benefit and must be weighed against its potential harms. Individualized treatment decisions with patient involvement remain essential.
Conclusion
This study adds to evidence that cyproterone acetate offers no breast development advantage over spironolactone and carries additional risks, making it a less favorable option in gender-affirming hormone therapy. Careful shared decision-making should guide antiandrogen selection.
References
Angus et al 2023 -- Effect of Spironolactone and Cyproterone Acetate on Breast Growth in Transgender People: A Randomized Clinical Trial
Additional sources 2023 -- Safety concerns related to cyproterone acetate
